IN2014KN02324A - - Google Patents
Info
- Publication number
- IN2014KN02324A IN2014KN02324A IN2324KON2014A IN2014KN02324A IN 2014KN02324 A IN2014KN02324 A IN 2014KN02324A IN 2324KON2014 A IN2324KON2014 A IN 2324KON2014A IN 2014KN02324 A IN2014KN02324 A IN 2014KN02324A
- Authority
- IN
- India
- Prior art keywords
- masp
- inhibitory agent
- subject
- amount
- mas
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 abstract 13
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 abstract 9
- 101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 abstract 5
- 101710117390 Mannan-binding lectin serine protease 1 Proteins 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 abstract 3
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 3
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 abstract 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 abstract 2
- 230000024203 complement activation Effects 0.000 abstract 2
- 210000003743 erythrocyte Anatomy 0.000 abstract 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 abstract 2
- 230000004083 survival effect Effects 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261621461P | 2012-04-06 | 2012-04-06 | |
| PCT/US2013/035488 WO2013180834A2 (fr) | 2012-04-06 | 2013-04-05 | Compositions et procédés d'inhibition de masp-1 et/ou masp-3 pour le traitement l'hémoglobinurie paroxysmique nocturne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN02324A true IN2014KN02324A (fr) | 2015-05-01 |
Family
ID=49325295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2324KON2014 IN2014KN02324A (fr) | 2012-04-06 | 2013-04-05 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20130273053A1 (fr) |
| EP (2) | EP3366307B1 (fr) |
| JP (3) | JP6366571B2 (fr) |
| KR (2) | KR102142508B1 (fr) |
| CN (1) | CN104661676A (fr) |
| AU (3) | AU2013267909B2 (fr) |
| BR (1) | BR112014024793A2 (fr) |
| CA (2) | CA2869326C (fr) |
| CL (1) | CL2014002694A1 (fr) |
| CY (1) | CY1120736T1 (fr) |
| DK (2) | DK3366307T3 (fr) |
| ES (2) | ES2670668T3 (fr) |
| HK (1) | HK1206996A1 (fr) |
| HR (1) | HRP20180671T1 (fr) |
| HU (1) | HUE036930T2 (fr) |
| IL (2) | IL234991B (fr) |
| IN (1) | IN2014KN02324A (fr) |
| LT (1) | LT2833907T (fr) |
| MX (2) | MX2018008658A (fr) |
| NO (1) | NO2881536T3 (fr) |
| NZ (2) | NZ781091A (fr) |
| PL (2) | PL2833907T3 (fr) |
| PT (1) | PT2833907T (fr) |
| RS (1) | RS57266B1 (fr) |
| RU (2) | RU2018114903A (fr) |
| SI (1) | SI2833907T1 (fr) |
| TR (1) | TR201806939T4 (fr) |
| WO (1) | WO2013180834A2 (fr) |
| ZA (1) | ZA201408100B (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107011443B (zh) * | 2011-05-04 | 2021-04-30 | 奥默罗斯公司 | 用于抑制masp-2依赖的补体活化的组合物 |
| EP4119577A3 (fr) * | 2012-06-18 | 2023-11-08 | Omeros Corporation | Compositions et procédés d'inhibition de masp-1 et/ou masp-2 et/ou masp-3 pour le traitement de diverses maladies et troubles |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| JP2016514456A (ja) * | 2013-03-15 | 2016-05-23 | オメロス コーポレーション | 生物活性ペプチド担持抗体を生成する方法およびそれを含む組成物 |
| JOP20170154B1 (ar) * | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
| JPWO2018097308A1 (ja) | 2016-11-28 | 2019-10-17 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| EP3546574A4 (fr) * | 2016-11-28 | 2020-09-09 | Chugai Seiyaku Kabushiki Kaisha | Domaine de liaison à l'antigène et polypeptide comprenant une section de transport |
| WO2018186322A1 (fr) * | 2017-04-03 | 2018-10-11 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-masp-1 et procédés d'utilisation |
| MX2020005220A (es) | 2017-11-28 | 2020-08-24 | Chugai Pharmaceutical Co Ltd | Polipeptido que incluye dominio de union al antigeno y seccion de transporte. |
| WO2019231935A1 (fr) * | 2018-05-29 | 2019-12-05 | Omeros Corporation | Inhibiteurs de masp-2 et procédés d'utilisation |
| WO2019230867A1 (fr) | 2018-05-30 | 2019-12-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprenant un domaine de liaison à l'aggrécane et une fraction de transport |
| AU2020323532A1 (en) * | 2019-07-31 | 2022-03-03 | Biocryst Pharmaceuticals, Inc. | Dosing regimens for oral complement Factor D inhibitors |
| WO2021113686A1 (fr) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Inhibiteurs de masp-2 et procédés d'utilisation |
| US12030853B2 (en) | 2019-12-04 | 2024-07-09 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| JP2023504543A (ja) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| CN114295594B (zh) * | 2021-12-06 | 2023-09-19 | 贵州理工学院 | 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| EP0438803B1 (fr) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccins contre le cancer et les maladies infectieuses |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| WO1994013804A1 (fr) | 1992-12-04 | 1994-06-23 | Medical Research Council | Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| CA2391402A1 (fr) * | 1999-12-02 | 2001-06-07 | Jens Christian Jensenius | Masp-3: enzyme de fixation du complement, et son utilisation |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| US7043719B2 (en) * | 2001-07-23 | 2006-05-09 | Intel Corporation | Method and system for automatically prioritizing and analyzing performance data for one or more, system configurations |
| ES2601143T3 (es) | 2002-07-19 | 2017-02-14 | Omeros Corporation | Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos |
| US7666627B2 (en) * | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
| US20060140939A1 (en) * | 2003-02-21 | 2006-06-29 | Fung Sek C M | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| EP1713929A2 (fr) * | 2004-02-03 | 2006-10-25 | Bayer HealthCare AG | Agents diagnostiques et therapeutiques pour des maladies associees a la kallikreine plasmatique (klkb1) |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US7803931B2 (en) * | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| MY169746A (en) | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ATE419671T1 (de) * | 2006-07-31 | 2009-01-15 | Fiat Ricerche | Durch eine fluidströmung betätigbarer elektrischer generator |
| JP5537420B2 (ja) | 2007-05-31 | 2014-07-02 | ユニヴァーシティ オブ ワシントン | 標的遺伝子の誘導性変異誘発 |
| CN102164960A (zh) * | 2008-09-26 | 2011-08-24 | 罗氏格黎卡特股份公司 | 双特异性抗-egfr/抗-igf-1r抗体 |
| US8637454B2 (en) * | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| US20120022543A1 (en) * | 2009-03-05 | 2012-01-26 | Smith & Nephew, Inc. | System, method, and apparatus for locating a femoral neck guide wire |
| WO2011006982A2 (fr) * | 2009-07-17 | 2011-01-20 | Rigshospitalet | Inhibiteurs de l'activation du complément |
| AU2010314931A1 (en) | 2009-11-05 | 2012-06-21 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| CN103781492A (zh) | 2011-04-08 | 2014-05-07 | 莱斯特大学 | 用于治疗与masp-2依赖性补体活化相关的状况的方法 |
-
2013
- 2013-04-05 RU RU2018114903A patent/RU2018114903A/ru unknown
- 2013-04-05 KR KR1020147030787A patent/KR102142508B1/ko active IP Right Grant
- 2013-04-05 EP EP18158799.9A patent/EP3366307B1/fr active Active
- 2013-04-05 ES ES13798222.9T patent/ES2670668T3/es active Active
- 2013-04-05 US US13/857,391 patent/US20130273053A1/en not_active Abandoned
- 2013-04-05 HU HUE13798222A patent/HUE036930T2/hu unknown
- 2013-04-05 PT PT137982229T patent/PT2833907T/pt unknown
- 2013-04-05 RU RU2014144621A patent/RU2655299C2/ru active
- 2013-04-05 LT LTEP13798222.9T patent/LT2833907T/lt unknown
- 2013-04-05 MX MX2018008658A patent/MX2018008658A/es unknown
- 2013-04-05 MX MX2014012045A patent/MX357540B/es active IP Right Grant
- 2013-04-05 PL PL13798222T patent/PL2833907T3/pl unknown
- 2013-04-05 NZ NZ781091A patent/NZ781091A/en unknown
- 2013-04-05 EP EP13798222.9A patent/EP2833907B1/fr active Active
- 2013-04-05 IN IN2324KON2014 patent/IN2014KN02324A/en unknown
- 2013-04-05 CA CA2869326A patent/CA2869326C/fr active Active
- 2013-04-05 KR KR1020207022397A patent/KR102318623B1/ko active IP Right Grant
- 2013-04-05 ES ES18158799T patent/ES2894944T3/es active Active
- 2013-04-05 JP JP2015504751A patent/JP6366571B2/ja active Active
- 2013-04-05 WO PCT/US2013/035488 patent/WO2013180834A2/fr active Application Filing
- 2013-04-05 AU AU2013267909A patent/AU2013267909B2/en active Active
- 2013-04-05 CN CN201380029994.3A patent/CN104661676A/zh active Pending
- 2013-04-05 CA CA3087933A patent/CA3087933A1/fr active Pending
- 2013-04-05 BR BR112014024793A patent/BR112014024793A2/pt not_active Application Discontinuation
- 2013-04-05 DK DK18158799.9T patent/DK3366307T3/da active
- 2013-04-05 TR TR2018/06939T patent/TR201806939T4/tr unknown
- 2013-04-05 DK DK13798222.9T patent/DK2833907T3/en active
- 2013-04-05 PL PL18158799T patent/PL3366307T3/pl unknown
- 2013-04-05 RS RS20180586A patent/RS57266B1/sr unknown
- 2013-04-05 SI SI201331032T patent/SI2833907T1/en unknown
- 2013-04-05 NZ NZ629675A patent/NZ629675A/en unknown
-
2014
- 2014-10-05 IL IL234991A patent/IL234991B/en active IP Right Grant
- 2014-10-06 CL CL2014002694A patent/CL2014002694A1/es unknown
- 2014-11-05 ZA ZA2014/08100A patent/ZA201408100B/en unknown
- 2014-12-04 NO NO14196403A patent/NO2881536T3/no unknown
-
2015
- 2015-08-10 HK HK15107717.0A patent/HK1206996A1/xx unknown
-
2018
- 2018-01-31 AU AU2018200721A patent/AU2018200721B2/en active Active
- 2018-04-26 HR HRP20180671TT patent/HRP20180671T1/hr unknown
- 2018-05-23 CY CY181100540T patent/CY1120736T1/el unknown
- 2018-07-03 JP JP2018126460A patent/JP6815355B2/ja active Active
-
2019
- 2019-02-26 US US16/285,741 patent/US20190382505A1/en not_active Abandoned
-
2020
- 2020-05-17 IL IL274721A patent/IL274721B/en unknown
- 2020-06-22 AU AU2020204163A patent/AU2020204163A1/en not_active Abandoned
- 2020-09-17 JP JP2020156216A patent/JP2021001199A/ja active Pending
-
2021
- 2021-10-11 US US17/498,521 patent/US20220242972A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN02324A (fr) | ||
| MX339002B (es) | El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
| WO2014188276A3 (fr) | Compositions d'antioxydants et procédés d'utilisation | |
| IN2015DN01156A (fr) | ||
| NZ727304A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| MX2011011950A (es) | Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas. | |
| WO2014113429A3 (fr) | Composés de type pyrrolopyrimidine substituée, compositions en contenant et méthodes de traitement faisant appel à eux | |
| WO2010083239A3 (fr) | Modulation thérapeutique de la lubrification limite de l'épithélium vaginal | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| MX367091B (es) | Una composición farmacéutica o cosmética tópica que comprende un extracto de la baya de la fruta milagrosa (synsepalum dulcificum) para usarse en el tratamiento o la prevención de desórdenes en la piel, mebrana mucosa, cabello, articulaciones y uñas. | |
| GB2489382A (en) | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | |
| MX2013004062A (es) | Analogos de ciclosporina. | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| MX2014000567A (es) | Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios. | |
| MX2015003074A (es) | Formulaciones que comprenden idebenona, n-acetil-s-farnesil-l-cist eína y ergotioneína y usos de las mismas. | |
| MX2018007871A (es) | Composiciones para el cuidado personal. | |
| EA201491532A1 (ru) | Фармацевтические композиции для использования в комплексной терапии | |
| MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| MX2013014630A (es) | Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida. | |
| TN2015000048A1 (en) | Methods of administering rifaximin for weight loss and treatment of obesity | |
| WO2016108572A3 (fr) | Composition visant à prévenir et à traiter les maladies liées au cholestérol | |
| WO2011091154A3 (fr) | Utilisation d'érythrocytes humains dans la prévention et le traitement de la dissémination et de la croissance du cancer |